Recent

% | $
Quotes you view appear here for quick access.

Infinity Pharmaceuticals, Inc. (INFI) Message Board

  • greenshotshut greenshotshut Jun 14, 2013 3:12 PM Flag

    Infinity Pharmaceuticals weakness an overreaction, says Stifelject

    After meeting with Infinity's management, Stifel views weakness in the shares following ASCO data as an overreaction. The firm thinks that the ASCO data reaffirmed that IPI-145 is an active drug in iNHL and CLL, and it views the drug as competitive with other hematological malignancy drugs that are being developed. The firm keeps a Buy rating on the stock.

    Sentiment: Strong Buy

 
INFI
1.54-0.06(-3.75%)Jul 22 4:00 PMEDT